Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis

Nature Reviews Rheumatology

Volumn 5, Issue 4, 2009, Pages 225-228

  Phillips, Kristine ^a   Byrne Dugan, Cathryn ^a   Batterson, Eric ^a   Seibold, James R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; DIFFUSE SCLERODERMA; DISEASE COURSE; FATALITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; RAYNAUD PHENOMENON;

ADULT; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; RAYNAUD DISEASE; SCLERODERMA, DIFFUSE;

EID: 67650470435     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.30     Document Type: Article

References (17)

1. Steen, V. D. & Medsger, T. A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66, 940-944 (2007).
2. Ostojic, P & Damjanov, N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin. Rheumatol. 25, 453-457 (2006).
3. Ostojic, P et al. Interstitial lung disease in systemic sclerosis. Lung 185, 211-220 (2007).
4. Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962-3970 (2006).
5. Highland, K. B. et al. The spectrum of scleroderma lung disease. Semin. Respir. Crit Care Med. 28, 418-429 (2007)
6. Diot, E. et al. Relationship between abnormalities on high-resolution ct and pulmonary function in systemic sclerosis. Chest 114, 1623–1629 (1998).
7. Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248-1259 13. (2008).
8. Plastiras, S. C. et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 55, 598-602 14. (2006).
9. Morgan, C. et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann. Rheum. Dis. 62, 146-150 (2003).
10. Baughman, R. P. & Raghu, G. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold? Am. J. Respir. Crit. Care Med. 177, 2-3 (2008).
11. Hsu, V. M. et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: a comparison of Doppler echocardiography, cardiac MRI, and ulmonary function test to right heart catheterization. J. Rheumatol. 35, 458-465 (2008).
12. Strange, C. & Seibold, J. R. Scleroderma lung disease: "if you don't know where you are going, any road will take you there". Am. J. Respir. Crit. Care Med. 177, 1178-1179 (2008).
13. Khanna, D. et al. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med. Decis. Making 28, 926-937 (2008).
14. Tashkin, D. P et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655-2666 (2006).
15. Tashkin, D. P. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 176, 1026-1034 (2007).
16. Nannini, C. et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and a meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res. Ther. 10, R124 (2008).
17. Wells, A. U. et al. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? Am. J. Respir. Crit. Care Med. 176, 952-953 (2007).